Article Text

PDF
The use of fluconazole in neonatal intensive care units
  1. P Manzoni1,
  2. M Mostert2,
  3. E Jacqz-Aigrain3,
  4. D Farina1
  1. 1
    Neonatology and NICU, S Anna Hospital, Turin, Italy
  2. 2
    Department of Paediatrics, University of Torino, Turin, Italy
  3. 3
    Department of Paediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center Inserm CIC 9202, Hopital Robert Debré, Paris, France
  1. Correspondence to Dr P Manzoni, Neonatology and NICU, S Anna Hospital. Azienda Ospedaliera Regina Margherita, S Anna, C so Spezia 60, 10126 Torino, Italy; paolomanzoni{at}hotmail.com

Abstract

Preterm neonates in neonatal intensive care units (NICU) are at high risk of invasive fungal infection (IFI), mostly by Candida spp. IFI in such patients is increasingly leading to high morbidity and mortality and frequent neurodevelopmental disabilities in the survivors. Most conditions and risk factors associated with neonatal IFI are unavoidable, being intrinsic to prematurity or related to the aggressive nature of the care these patients require. Neonatal IFI is difficult to diagnose, as candidaemia may be transient and difficult to eradicate due to the high rates of end-organ dissemination. The best option to decrease the burden of disease is thus to prevent it. Fluconazole administration is a suitable strategy and proved effective in many retrospective, single-centre studies and in four randomised, prospective clinical trials. Nevertheless, the use of this azole in high-risk preterm neonates in NICU is not yet a standard of care. This article summarises current evidence on the use of fluconazole in preterm neonates and discusses the concerns surrounding its use in nurseries.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Contributors EJ-A and PM are, respectively, coordinator and workpackage leader of the FP7 European Project Treat Infections in Neonates (TINN). All four authors gave important contribution in terms of writing, reviewing and translating the manuscript.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.